Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection

Abstract

Gastric colonization by Helicobacter pylori increases the risk of gastric disorders, including atrophic gastritis which can be diagnosed based on levels of serum biomarkers like Gastrin and Pepsinogen. We therefore examined the efficacy of a serological-based method namely GastroPanel Blood kit, in diagnosing and scoring gastritis associated to Helicobacter pylori infection.

Atrophic Gastritis and Gastric Cancer Risk amongst Diabetes Mellitus Type 2 Subjects and Controls in Yaounde Cameroon Using a Panel of Serum Biomarkers (PGI, G-17)

“…These figures are however in sharp contrast to those reported in by Storskrubb, et al [14] in Sweden and Telarata, et al [15] in Finland where the overall prevalence of atrophic gastritis was only 6.5% and 3.5% respectively. These results are also similar with what has been reported previously in Cameroon by Noah, et al [16] and Ebule, et al [17] who obtained respectively 8.1% and 6.6% for atrophic gastritis. The prevalence of 9.8% atrophic corpus gastritis is in contrast to what has been reported earlier amongst dyspeptic subjects of 3.5%.…”

Systematic review with meta‐analysis: diagnostic performance of the combination of pepsinogen, gastrin‐17 and anti‐Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis

“…48 Of the 39 articles, 15 met the criteria for the inclusion in the review. 7,12,15,[18][19][20]23,26,30,33,35,38,42,47,48 In addition, a total of five abstracts that met inclusion criteria were identified from the conferences proceedings. [49][50][51][52][53] Finally, a total of 20 studies consisting of 15 papers and five abstracts were included in the meta-analysis.…”

“…18 Fifteen studies were conducted in Europe, 7,12,15,19,20,23,26,33,35,42,[49][50][51][52][53] three in Russia, 18,47,48 one in Japan, 30 and one in Africa. 38 Fourteen studies were performed in a single centre, 7,15,18,20,23,30,33,38,[48][49][50][51][52][53] and six were multicentre studies. 12,19,26,35,42,47 All studies had a cohort design, except three that were case-control studies.…”

“…12,19,26,35,42,47 All studies had a cohort design, except three that were case-control studies. 7,35,52 Seventeen studies assessed the diagnostic performance of the panel test in patients with upper gastrointestinal symptoms referred to endoscopy, 7,12,15,[18][19][20]23,30,33,35,38,42,48,[50][51][52][53] while three studies were performed in the community. 26,47,49 All studies, but one where HpAb were detected using Helori-test IgG (Eurospital, Italy), 20 used the serum assays of the GastroPanel (Biohit, Finland).…”

“…Eleven studies used as target condition atrophic gastritis regardless of the grade of severity (from mild to severe atrophy), 18,20,23,33,38,42,[47][48][49][50]52 seven studies used moderate-severe atrophic gastritis 7,12,19,26,30,35,51 and two studies reported the results for both target conditions separately. 15,53 ZAGARI ET AL.…”